<?xml version="1.0" encoding="UTF-8" standalone="no"?>
<ibecs-document>
<record>
<header>
<identifier>ibc-100229</identifier>
<setSpec>1138-3593</setSpec>
</header>
<metadata xmlns="http://example.org/myapp/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:dcterms="http://purl.org/dc/terms/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://example.org/myapp/schema.xsd">
<dc:title xml:lang="en">Prevalence of Neuropathic Pain according to the NP4 test in Primary Care</dc:title>
<dc:description xml:lang="en">Background. Primary Care Physicians are usually the first to see patients with neuropathic pain. The aim of this study is to assess the prevalence of neuropathic pain, its therapeutic management, and to clinically characterize these patients. Material and methods. An epidemiological, observational, cross-sectional study was carried out in Spanish Primary Care settings. The first 25 patients older than 18 years with any type of pain (a total of 16,115) were registered, and the first 5 with a high neuropathic pain component according to the NP4 test, and was clinically confirmed (n= 3,836) were included in the study. Pain intensity and impact on daily activities, as well as overall satisfaction with treatment were assessed. Results. A total of 45.7% of patients had neuropathic pain according to NP4 test. The median age was 59 years, and 60% were women. Patients took a mean of 2.4 drugs, with NSAIDs (53%) and non-opioid analgesics (51%) being the most common. The scores for Pain intensity and interference in daily activities were both 6.2. The overall opinion of the SATMED-Q test was 47.3/100, which was 1.4 points lower than the standardised score according to Spanish population. Conclusions. Neuropathic pain according to NP4 test is highly prevalent in Spanish Primary Care settings. The management of these patients with NSAIDs and non-opioid analgesics is not appropriate, as they are not recommended for this kind of pain. Although they were being treated with more than 2 analgesics, they still referred to high pain intensity, interference in daily activities, and a low general opinion of the treatment (AU)</dc:description>
<dc:creator>Pérez, M</dc:creator>
<dc:creator>Galvez, R</dc:creator>
<dc:creator>Blanco, E</dc:creator>
<dc:creator>Zamorano, E</dc:creator>
<dc:creator>López, V</dc:creator>
<dc:language>es</dc:language>
<dc:description xml:lang="es">Introducción. El médico de atención primaria suele ser el primero en atender a pacientes con dolor neuropático. Se pretende evaluar la prevalencia del dolor neuropático, su manejo terapéutico y la caracterización clínica de estos pacientes. Material y métodos. Estudio epidemiológico, observacional y transversal realizado en centros de atención primaria de España. Registro de los primeros 25 pacientes &amp;#8805; 18 años con dolor de cualquier tipo (total 16.115) e inclusión de los 5 primeros con alto componente neuropático identificados mediante DN4 y confirmados clínicamente (3.836 evaluables). Se valoró la intensidad e impacto del dolor sobre las actividades diarias y la satisfacción con el tratamiento. Resultados. El 45,7% de los pacientes presentaron dolor neuropático según DN4. La edad media era 59 años y un 60% eran mujeres. Los pacientes utilizaban una media global de 2,4 fármacos los 3 meses previos al estudio, principalmente antiinflamatorios no esteroideos (AINE) (53%) y analgésicos no opioides (51%). Las puntuaciones de la intensidad del dolor e interferencia sobre las actividades diarias fueron ambas 6,2. La opinión general del SATMED-Q fue 47,3/100 que está 1,4 puntos por debajo de la obtenida por la población general española. Conclusiones. El dolor neuropático, según cuestionario DN4, es muy prevalente en los centros de atención primaria españoles. El manejo de estos pacientes con AINE y analgésicos no opioides no es adecuado, ya que no están recomendados para este tipo de dolor, y aun siendo tratados con más de 2 fármacos, los pacientes continúan presentando un dolor moderado con interferencia sobre sus actividades (AU)</dc:description>
<dc:source>SEMERGEN, Soc. Esp. Med. Rural Gen. (Ed. Impr.);38(4): 203-210, mayo 2012. tab, ilus</dc:source>
<dc:identifier>ibc-100229</dc:identifier>
<dc:title xml:lang="es">Prevalencia del dolor neuropático (DN), según DN4, en atención primaria</dc:title>
<dc:subject>^d23938^s22080</dc:subject>
<dc:subject>^d7435^s37748</dc:subject>
<dc:subject>^d^s22083</dc:subject>
<dc:subject>^d28608^s22048</dc:subject>
<dc:subject>^d21034</dc:subject>
<dc:subject>^d29310</dc:subject>
<dc:subject>^d21030</dc:subject>
<dc:subject>^d28608^s22074</dc:subject>
<dc:subject>^d21044</dc:subject>
<dc:subject>^d28596^s22045</dc:subject>
<dc:subject>^d9630^s22080</dc:subject>
<dc:subject>^d7435^s22048</dc:subject>
<dc:subject>^d11756^s22049</dc:subject>
<dc:subject>^d9062</dc:subject>
<dc:subject>^d10333^s22080</dc:subject>
<dc:subject>^d11756^s22048</dc:subject>
<dc:subject>^d11756^s22045</dc:subject>
<dc:subject>^d11756^s22066</dc:subject>
<dc:type>article</dc:type>
<dc:date>201205</dc:date>
</metadata>
</record>
</ibecs-document>
